Leerink Partners Remains Bullish After traveling with Hologic (HOLX) Management

Leerink Partners reiterated an Outperform rating and $46.00 price target on Hologic (NASDAQ: HOLX) after traveling with management. Consistent with Street projections, Leerink models ~4% organic growth in FY17 and expects management will likely establish an initial FY17 guidance range that brackets this figure.

Analyst Richard Newitter commented, "HOLX remains a top mid/large-cap pick following recent diligence and time on the road with management. We have increased confidence HOLX can be a sustainable MSD top-line grower over the next several years with several underappreciated drivers beyond US 3D Tomo capital sales (OUS acceleration, R&D pipeline emphasis, 3D service rev), and more meaningful top-line acceleration into the out-years is a real possibility, especially when factoring in tuck-in M&A potential. We also continue to view HOLX as one of the more dependable double-digit (sustainable low-teens) EPS growth stories in MedTech with strong est. upside prospects, and an above-avg. 7% FCF yield. Reiterate OP & $46 PT."

For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.

Shares of Hologic closed at $38.14 yesterday.

You May Also Be Interested In

• Roth/MKM Upgrades Albertsons Companies Inc. (ACI) to Buy, 'Fundamental Floor and Improved Deal Likelihood'
• Lake Street Capital Markets Starts Research Solutions Inc. (RSSS) at Buy
• Goldman Sachs First Take on Tata Consumer Products (TGBL:IN) Earnings